Viking Therapeutics Stock Surges 30%. It Could Challenge Lilly and Novo’s Obesity Empire.

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly. Continue Reading

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.